Project description
New ways to tackle metabolic liver disease
Metabolic associated fatty liver disease (MAFLD) affects approximately 25 % of Europe’s population. Progressing from silent stages to severe complications like cirrhosis and hepatocellular carcinoma (HCC), MAFLD poses significant health risks. Often, patients succumb not to the liver ailment itself, but to associated cardiovascular issues. In this context, the EU-funded ARTEMIS project will merge computational mechanistic and machine learning models to furnish clinicians with ‘virtual twins’ through a Clinical Decision Support System. These virtual counterparts promise personalised management, spanning from latent stages to critical complications like cirrhosis and HCC. Notably, ARTEMIS forecasts disease progression and cardiovascular risks and evaluates treatment strategies, advocating for proactive patient surveillance. With its predictive capabilities, ARTEMIS heralds a paradigm shift in MAFLD care.
Objective
The ARTEMIs project aims to consolidate existing computational mechanistic and machine-learning models at different scales to deliver ‘virtual twins’ embedded in a clinical decision support system (CDSS). The CDSS will provide clinically meaningful information to clinicians, for a more personalised management of the whole spectrum of Metabolic Associated Fatty Liver Disease (MAFLD). MAFLD, with an estimated prevalence of about 25%, goes from an undetected sleeping disease, to inflammation (hepatitis), to fibrosis development (cirrhosis) and/or hepatocellular carcinoma (HCC), decompensated cirrhosis and HCC being the final stages of the disease. However, many MAFLD patients do not die from the liver disease itself, but from cardiovascular comorbidities or complications.
The ARTEMIs will contribute to the earlier management of MAFLD patients, by prognosing the development of more advanced forms of the disease and cardiovascular comorbidities, promoting active surveillance of patients at risk. The system will predict the impact of novel drug treatments or procedures, or simply better life habits. The system will therefore not only serve as a clinical decision aid tool, but also as an educational tool for patients, to promote better nutritional and lifestyle behaviors.
In more advanced forms of the disease, therapeutic interventions include TIPPS to manage portal hypertension, partial hepatectomy, partial or complete liver transplant. ARTEMIs will contribute to predict per- or post-intervention heart failure, building on existing microcirculation hemodynamics models.
The model developers will benefit from a large distributed patient cohort and data exploration environment to identify patterns in data, draw new theories on the liver-heart metabolic axis and validate the performance of their models.
The project includes a proof-of-concept feasibility study assessing the utility of the integrated virtual twins and CDSS in the clinical context.
Fields of science
Keywords
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
28050 MADRID
Spain
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participants (18)
75013 Paris
See on map
75012 Paris
See on map
07747 Jena
See on map
08035 Barcelona
See on map
69120 Heidelberg
See on map
1200 Bruxelles / Brussel
See on map
52621 Ramat Gan
See on map
46026 Valencia
See on map
10117 Berlin
See on map
00185 Roma
See on map
1090 Wien
See on map
78153 Le Chesnay Cedex
See on map
69120 Heidelberg
See on map
79098 Freiburg
See on map
04109 Leipzig
See on map
31670 Labege
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1050 Bruxelles / Brussel
See on map
500 02 HRADEC KRALOVE
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (2)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
BH12 5BB Poole
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SW7 2AZ LONDON
See on map